Monitoring cancer therapy with PET: Probably effective, but more research is needed

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 9, 2009, Pages 1520-1525

  Lucignani, Giovanni ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; IRINOTECAN;

BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; REVIEW; TREATMENT RESPONSE; TUMOR VOLUME; WHOLE BODY SCINTISCANNING;

CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 68949218312     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1214-x     Document Type: Review

References (14)

1. http://nobelprize.org/nobel-prizes/medicine/laureates/1966/rous-bio.html.
2. EA Eisenhauer P Therasse J Bogaerts LH Schwartz D Sargent R Ford, et al 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 11) Eur J Cancer 45 2 228 47
3. K Herrmann BJ Krause RA Bundschuh T Dechow M Schwaiger 2009 Monitoring response to therapeutic interventions in patients with cancer Semin Nucl Med. 39 3 210 32
4. MR Benz J Czernin MS Allen-Auerbach WD Tap SM Dry D Elashoff, et al 2009 FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas Clin Cancer Res. 15 8 2856 63
5. M Feng FM Kong M Gross S Fernando JA Hayman RK Ten Haken 2009 Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing Int J Radiat Oncol Biol Phys. 73 4 1228 34
6. K Hamada Y Tomita A Inoue T Fujimoto N Hashimoto A Myoui, et al 2009 Evaluation of chemotherapy response in osteosarcoma with FDG-PET Ann Nucl Med. 23 1 89 95
7. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer Ann Oncol. 20 6 1057 61
8. Cerfolio RJ, Bryant AS, Talati AA, Eloubeidi MA, Cerfolio RM, Winokur TS. Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders. J Thorac Cardiovasc Surg. 2009 Mar;137(3):605-9. Erratum in: J Thorac Cardiovasc Surg. 2009 Jun;137(6):1581. Eloubeidi, Mohamad A [added].
9. A Kumar R Kumar V Seenu SD Gupta M Chawla A Malhotra, et al 2009 The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Eur Radiol. 19 6 1347 57
10. DJ Sargent L Rubinstein L Schwartz JE Dancey C Gatsonis LE Dodd, et al 2009 Validation of novel imaging methodologies for use as cancer clinical trial end-points Eur J Cancer 45 2 290 9
11. LK Shankar A Van den Abbeele J Yap R Benjamin S Scheutze TJ Fitzgerald 2009 Considerations for the use of imaging tools for phase II treatment trials in oncology Clin Cancer Res. 15 6 1891 7
12. SM Larson H Schoder 2009 New PET tracers for evaluation of solid tumor response to therapy Q J Nucl Med Mol Imaging 53 2 158 66
13. GJ Kelloff JM Hoffman B Johnson HI Scher BA Siegel EY Cheng, et al 2005 Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development Clin Cancer Res. 11 8 2785 808
14. WC Eckelman RC Reba GJ Kelloff 2008 Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine Drug Discov Today 13 17-18 748 59